Neuraltus Pharmaceuticals Readies Second Phase 2 Study of Potential ALS Therapy

Neuraltus Pharmaceuticals Readies Second Phase 2 Study of Potential ALS Therapy

Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the intent of confirming positive earlier findings in patients with elevated levels of baseline inflammation and further evaluating the drug’s efficacy. Inflammation is thought to be a…

11 Common Symptoms and Effects of Motor Neurone Disease

According to the Motor Neurone Disease Association, here are some common symptoms and effects of MND: Discomfort and pain: although they do not come from MND directly. Muscle cramps and spasms: which may be eased by changing positions. If you feel these changes are not enough, talk to your doctor. Stiff joints: some slow…

7 ALS Headlines

1. Herantis’ Potential ALS Treatment, CDNF, Recommended for Orphan Drug Status by EMA Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on…

ALS – Canadian Adult Stem Cell Research

https://www.youtube.com/watch?v=XJE8OxUn0d4 In this video by the Adaptive Canuck ALS Foundation, learn more about their work with families living with ALS and with adult stem cell research. Learn more about ALS here: https://bit.ly/ALSNewsToday…

13 ALS Facts You Should Know About

ALS, or amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. A-myo-trophic comes from the Greek language. “A” means no. “Myo” is referring to the muscle, and “Trophic” means nourishment –…

ALS Awareness – Les Turner ALS Foundation

https://www.youtube.com/watch?v=emZjNcD484E In this Comcast NewsmakersIL video, learn more about the Les Turner ALS Foundation. “Since 1977, the Les Turner ALS Foundation has been Chicagoland’s leader in patient services, research, and education for Amyotrophic Lateral Sclerosis (ALS). The foundation serves nearly 90% of people living with ALS in the Chicagoland…

Novel Prodrug with Potential for ALS and Like Diseases Acquired by Startup, Yumanity Therapeutics

Yumanity Therapeutics has recently licensed a prodrug invented at the University of Arizona (UA), adding it to the company’s expanding platform of potential therapies for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). Neurodegenerative diseases result from errors made during the building and folding processes of proteins within the cell. In 2009, UA…